Emerging data suggest that peroxisome proliferator-activated receptor- ? (PPAR-?) is a critical determinant that may provide functional links between diabetes and CVD. During the past cycle of this R01 funding, our laboratory has made a series of significant contributions to better understand the role of PPAR-? activation in the vasculature. The insulin-sensitizing thiazolidinediones (TZDs) are synthetic ligands of PPAR-? and the first drugs used to treat insulin resistance in patients with type 2 diabetes. Despite of their effectiveness as insulin sensitizers and their protective effects in the vasculature, the therapeutic efficacy of TZDs has been severely compromised due to the appearance of associated cardiovascular events. Thus, the investigation of the molecular mechanisms underlying PPAR-? functions especially in the cardiovascular system are of utmost importance. Of significance, we have identified a nitric oxide (NO) and fatty acid-derived product, nitrated derivatives of fatty acids (NO2-FA) including nitrated oleic acid (OA- NO2) and linoleic acid (LNO2), as potent endogenous PPAR ? ligands. More recent analysis by our laboratories clearly documented that NO2-FA-activated PPAR ? recruits/displaces differential cofactors leading to a pattern of gene expression that mediate different biological responses compared to TZD-activated PPAR ?. Also, we have identified Kruppel-like factor 11 (KLF11) as a novel PPAR3 cofactor. Although KLF11 gene mutations cause MODY7, an early-onset type 2 diabetes mellitus, but its role in the vasculature is entirely unknown. Based on these key results, in this proposal we will test the central hypothesis that NO2-FA-modulated PPAR ? activation and the recruitment of KLF11 play a critical role in protecting the vasculature from vascular lesion formation, thereby contributing to maintenance of vascular homeostasis. Specifically, we will 1) Determine the molecular interactions between NO2-FA and PPAR-? in vascular remodeling;2) Define KLF11 as a novel PPAR-? cofactor required for PPAR-? function during vascular lesion formation. Advances in understanding the mechanisms of endogenous PPAR-? modulation will provide novel therapeutic strategies for treating diabetes and CVD.

Public Health Relevance

Cardiovascular diseases (CVD) are the primary cause of mortality among diabetic patients accounting for almost 2 out of 3 deaths. The insulin-sensitizing thiazolidinediones (TZDs) are synthetic ligands of PPAR-? and the first drugs used to treat insulin resistance in patients with type 2 diabetes. Despite of their effectiveness as insulin sensitizers and their protective effects in the vasculature, the therapeutic efficacy of TZDs has been severely compromised due to the appearance of associated cardiovascular events. This proposal will explore mechanisms how the endogenous PPAR-? ligands, nitro-fatty acids modulate PPAR-? signaling to inhibit vascular lesion formation. The successful implementation of this proposal should lead to a better understanding of endogenous signaling actions of nitro-fatty acids in the vasculature and will provide novel approaches to develop the next generation of PPAR-? drugs with anti-diabetic and anti-CVD properties.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL068878-12
Application #
8211994
Study Section
Special Emphasis Panel (ZRG1-VH-F (02))
Program Officer
Hasan, Ahmed AK
Project Start
2002-01-01
Project End
2015-11-30
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
12
Fiscal Year
2012
Total Cost
$388,750
Indirect Cost
$138,750
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Fan, Yanbo; Lu, Haocheng; Guo, Yanhong et al. (2016) Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice. Gastroenterology 150:1208-18
Zhang, Haoming; Lauver, D Adam; Wang, Hui et al. (2016) Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis. J Pharmacol Exp Ther 359:11-7
Zhang, Ji; Qiao, Congzhen; Chang, Lin et al. (2016) Cardiomyocyte Overexpression of FABP4 Aggravates Pressure Overload-Induced Heart Hypertrophy. PLoS One 11:e0157372
Villacorta, Luis; Gao, Zhen; Schopfer, Francisco J et al. (2016) Nitro-fatty acids in cardiovascular regulation and diseases: characteristics and molecular mechanisms. Front Biosci (Landmark Ed) 21:873-89
Zhang, J; Yuan, L; Zhang, X et al. (2016) Altered long non-coding RNA transcriptomic profiles in brain microvascular endothelium after cerebral ischemia. Exp Neurol 277:162-70
Guo, Yanhong; Garcia-Barrio, Minerva T; Wang, Laiyuan et al. (2016) Experimental Biology for the Identification of Causal Pathways in Atherosclerosis. Cardiovasc Drugs Ther 30:1-11
Li, Shen; Wang, Yan-Ning; Niimi, Manabu et al. (2016) Angiotensin II Destabilizes Coronary Plaques in Watanabe Heritable Hyperlipidemic Rabbits. Arterioscler Thromb Vasc Biol 36:810-6
Yin, Ke-Jie; Hamblin, Milton; Fan, Yanbo et al. (2015) Krüpple-like factors in the central nervous system: novel mediators in stroke. Metab Brain Dis 30:401-10
Guo, Yanhong; Fan, Yanbo; Zhang, Jifeng et al. (2015) Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. J Clin Invest 125:3819-30
Meng, Zhuo-Xian; Wang, Lin; Chang, Lin et al. (2015) A Diet-Sensitive BAF60a-Mediated Pathway Links Hepatic Bile Acid Metabolism to Cholesterol Absorption and Atherosclerosis. Cell Rep 13:1658-69

Showing the most recent 10 out of 81 publications